UNSPSC 51321803: Biclofibrate

This classification denotes an anti-lipidemic agent with the molecular formula C20H21Cl2NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 73U81R979T, chemically known as bis(p-chlorophenoxy)-acetic acid, 1-methyl-2-pyrrolidinylmethyl ester but generally known as biclofibrate, which bears US NIH Compound Identifier 185458. European Medicines Agency schedules Biclofibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05820MIG.

UNSPSC 51321803 Biclofibrate is a Commodity code covering a specific pharmaceutical active ingredient, but recent state and local procurement activity under this code does not focus on biclofibrate in isolation—instead, issuing bodies are procuring advanced life support medications, generic multi-source pharmaceuticals, and over-the-counter products through group purchasing mechanisms and direct vendor agreements. State and local buyers under this code include municipal fire rescue departments, state health and human services commissions, and cooperative purchasing alliances spanning multiple states. The work involves supplying finished pharmaceutical products (tablets, vials, injections) with defined expiration dates, storage requirements, and regulatory compliance documentation including Safety Data Sheets, cGMP certifications, and Drug Supply Chain Security Act compliance. Vendors must maintain relationships with authorized wholesalers and agree to pricing models ranging from flat rates to net price and WAC-minus structures, with administrative fees typically in the 3 to 5 percent range applied to purchases rather than upfront contract values.

Recent activity clusters in Florida, Texas, and Minnesota. The City of Tampa Fire Rescue issued IFB 26P00188 for Advanced Life Support Medications (due April 8, 2026; estimated value $40,000) requiring four specific medication line items with nine-month minimum expiration dates, ten-day delivery, and a Small Local Business Enterprise sheltered market designation offering a 5 percent bid discount. The Texas Health and Human Services Commission issued RFI HHS0017013 (due April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling the state's intent to develop direct contracting models outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products, requiring NDC and SKU specifications, wholesaler relationships with three named distributors, and 75 percent weight on price competitiveness. MMCAP awards span participating states including Oregon and take effect July 1, 2026.